Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
暂无分享,去创建一个
W. Symmans | H. Rugo | C. Geyer | N. Wolmark | S. Loibl | M. Untch | G. von Minckwitz | J. Huober | J. O’Shaughnessy | W. Sikov | P. Rastogi | M. Golshan | O. Metzger Filho | D. Maag | D. Sullivan | M. McKee | K. McIntyre | J. P. Ponce Lorenzo | Xuan Liu | J. P. Ponce Lorenzo